Navigation
banner

CNS Diseases Summit

2017-09-192017-08-112017-07-14
Register 3 for the price of 2 with the coupon code rcdvb!


registration button

Subscribe for updates




Dear Colleague,

We are excited to announce the CNS Diseases Summit, to be held on September 11-12, 2017 in Boston, MA. This meeting provides an interactive learning and relationship-building forum for all players in the CNS field. Colleagues from industry, academia, government agencies, and financing bodies will gather at the interface of research, partnerships, funding, and commercialization to find ways to move forward in a field that has been troubled with clinical failures.

The program will provide a comprehensive look at the current state of CNS, from research to commercialization. Above all, this event will provide networking opportunities in an intimate and accessible environment.

We invite you to join us as we connect, build relationships, and seek new ways forward into the future of CNS research and development.

Session Topics:

Joint Plenary Sessions:
I. Opening Keynote Session – Historical Perspective & Current State of the Industry
II. Round Table Discussions: Neuroinflammation, Neuroimaging & Translational Biomarkers
III. Ready, Set, Grow – New Company/Technology Pitch Competition
IV. Award Ceremony & Closing Keynote Session – Predictions for the Future

11th Neurodegenerative Diseases Research & Development
I. Experimental Therapeutics & Approaches in Alzheimer’s Disease & Related Dementias
II. Advances in Parkinson’s Disease Research & Therapeutics
III. Next Frontier in Multiple Sclerosis to Limit or Reverse Neurodegeneration
IV. Therapeutics for Rare & Orphan CNS Disorders

10th CNS Partnering & Deal-making
I. What’s New in CNS – Targets, Models, Assays, etc.
II. Industry Partnering with Academia & CROs to Advance Research
III. CNS Perspectives from Venture Capital & Public Markets
IV. Technology Transfer & Licensing: Challenges & Opportunities


We hope to see you there!

 

Best regards,

The 2017 Advisory Committee

 

2017 Advisory Board Members
Mark Allegretta, National Multiple Sclerosis Society
Patrick Brundin, Van Andel Research Institute
Roopali Gandhi, Harvard Medical School
Arti Gaur, Dartmouth Geisel School of Medicine
Linda Hedley, Hedley Consulting
Ole Isacson, Harvard Medical School
Satish Medicetty, GTCbio
Katrina Paumier, Michigan State University
Suzana Petanceska, National Institute on Aging, NIH
Robert Scannevin, Yumanity
Malu Tansey, Emory University
Harry Tracy, President, NI Research
Shafique Virani, BridgeBio 
Cheryl Wellington, University of British Columbia
Iva Toudjarska, Halloran Consulting Group
Charles Duncan, Piper Jaffray & Co.
Christine Brennan, Novartis Venture Fund